Regeneron Takes Legal Action Against Sandoz to Block Eylea Biosimilar

Regeneron Pharmaceuticals has sued Sandoz Group AG in federal court to block the sale of Enzeevu, a recently approved biosimilar version of Regeneron's eye drug Eylea.
The lawsuit alleges that Sandoz infringed on multiple patents related to Eylea, seeking damages and an order to prevent the sale of the biosimilar.
This legal action is part of Regeneron's broader strategy to protect its market exclusivity for Eylea, which has been facing competition from biosimilars.
Key patent protections for Eylea are set to expire this year, prompting Regeneron to take legal action against several companies developing biosimilars, including Amgen and Viatris.
The FDA has approved two interchangeable biosimilars to Eylea, Yesafili and Opuviz, but their launch in the U.S. is currently blocked by court injunctions.